Published in Toxins (Basel) on February 24, 2017
dbSNP: the NCBI database of genetic variation. Nucleic Acids Res (2001) 76.97
UniProt: the Universal Protein knowledgebase. Nucleic Acids Res (2004) 29.05
Immunotoxin therapy of cancer. Nat Rev Cancer (2006) 3.93
Understanding the mode of action of diphtheria toxin: a perspective on progress during the 20th century. Toxicon (2001) 2.24
Ovca1 regulates cell proliferation, embryonic development, and tumorigenesis. Genes Dev (2004) 2.04
Identification of the proteins required for biosynthesis of diphthamide, the target of bacterial ADP-ribosylating toxins on translation elongation factor 2. Mol Cell Biol (2004) 1.76
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res (2011) 1.54
DPH5, a methyltransferase gene required for diphthamide biosynthesis in Saccharomyces cerevisiae. Mol Cell Biol (1992) 1.46
Immunotoxins for leukemia. Blood (2014) 1.33
Immunotoxins: the role of the toxin. Toxins (Basel) (2013) 1.13
Diphthamide modification of eEF2 requires a J-domain protein and is essential for normal development. J Cell Sci (2008) 1.08
Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Cancer Genomics Proteomics (2014) 1.04
Expression of OVCA1, a candidate tumor suppressor, is reduced in tumors and inhibits growth of ovarian cancer cells. Cancer Res (1999) 1.02
Toxin-based therapeutic approaches. Toxins (Basel) (2010) 1.00
COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res (2016) 0.99
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy. Proc Natl Acad Sci U S A (2012) 0.96
The biosynthesis and biological function of diphthamide. Crit Rev Biochem Mol Biol (2013) 0.92
Dph3 is an electron donor for Dph1-Dph2 in the first step of eukaryotic diphthamide biosynthesis. J Am Chem Soc (2014) 0.92
A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene. J Biol Chem (2013) 0.89
The diphthamide modification pathway from Saccharomyces cerevisiae--revisited. Mol Microbiol (2014) 0.87
Gene trap mutagenesis-based forward genetic approach reveals that the tumor suppressor OVCA1 is a component of the biosynthetic pathway of diphthamide on elongation factor 2. J Biol Chem (2005) 0.84
Insights into diphthamide, key diphtheria toxin effector. Toxins (Basel) (2013) 0.84
New Life for Immunotoxin Cancer Therapy. Clin Cancer Res (2015) 0.83
Methylation of the DPH1 promoter causes immunotoxin resistance in acute lymphoblastic leukemia cell line KOPN-8. Leuk Res (2013) 0.81
Loss of diphthamide pre-activates NF-κB and death receptor pathways and renders MCF7 cells hypersensitive to tumor necrosis factor. Proc Natl Acad Sci U S A (2015) 0.79
Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins (Basel) (2016) 0.78